Anushka Bhrdwaj
Anushka Bhrdwaj has a total of 35 co-authors. Here are the top co-authors by number of shared publications:
- Anuraj Nayarisseri
In silico Research Laboratory, Eminent Biosciences, Indore, India
6 shared publications - Khushboo Sharma
In silico Research Laboratory, Eminent Biosciences, 91, Sector-A, Mahalakshmi Nagar, Indore – 452010, Madhya Pradesh, India
4 shared publications - Sanjeev Kumar Singh
Computer Aided Drug Design and Molecular Modeling Lab, Department of Bioinformatics, Alagappa University, Karaikudi, India
4 shared publications - Tajamul Hussain
Center of Excellence in Biotechnology Research, King Saud University, Riyadh 11451, Saudi Arabia
4 shared publications - Arshiya Khan
In silico Research Laboratory, Eminent Biosciences, 91, Sector-A, Mahalakshmi Nagar, Indore – 452010, Madhya Pradesh, India
3 shared publications - Ishita Chopra
In Silico Research Laboratory, Eminent Biosciences, Indore, Madhya Pradesh, India
3 shared publications
Latest Publications
- Open Access
- 16 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-30
Characterization of natural therapeutic compounds producing novel bacterial strains isolated from Hyderabad, India
Natural products (NPs) are secondary metabolites that exert their biological effects within and on other organisms. Bacteria are considered potent producers of bioactive natural compounds, due to their versatile biocatalytic activity. The present study aims to isolate, identify, and analyze four novel bacterial strains that have the potential to produce NPs. The novelty was determined via taxonomical assessment using various biochemical and quantitative antagonistic screening assays. 16S rRNA molecular characterization and bioinformatics analysis identified the isolates as Klebsiella pneumoniae strain ABSKSLAB01, Klebsiella quasipneumonia strain ABSKSLAB02, Streptomyces minutiscleroticus strain ABSKSLAB03, and Streptomyces peucetius strain ABSKSLAB04. Their bacterial sequences were deposited in the GenBank database with accession numbers ‘OP597532’, ‘OP597545’, ‘OQ061473’, and ‘PP086938’, respectively. Among all the bacterial strains, ABSKSLAB04 demonstrated the highest antagonistic activity and the potential to produce NPs. Further optimization studies using the OVAT approach and statistical investigations via Plackett–Burman, RSM–Box–Behnken design, and artificial neural network rendered the optimized culture conditions to produce NPs: pH 7 ± 1.2, temperature 40 ± 5 °C, and inositol concentration of 5.5 ± 1.5, resulting in maximum antagonistic activity of 29.81 mm. The ANN model reflected superior predictive capacity compared to the RSM model with enhanced statistical metrics: R2 (92.23%), MSE (0.0277), and RMSE (0.1477). ANN optimized production yield was measured at 580 mg/L, reflecting a 1.57-fold enhancement over the pre-optimized conditions (370 mg/L), and a 1.22-fold improvement compared to the RSM model (450 mg/L). This highlighted the ANN model’s robustness in modeling complex nonlinear relationships and optimizing the bioprocess parameters with higher fidelity. Therefore, the results from the study conclude the potential of the designated bacterial strain (ABSKSLAB04) to produce NPs with enhanced antimicrobial and antineoplastic characteristics. The strain can further be utilized in biotechnological paradigms by scaling up in the pharmaceutical and industrial sectors for therapeutic applications.
- 16 July 2025
- Published by Springer Nature in Scientific Reports
- Vol. 15 (1) , 1-30
Open AccessCharacterization of natural therapeutic compounds producing novel bacterial strains isolated from Hyderabad, India
Natural products (NPs) are secondary metabolites that exert their biological effects within and on other organisms. Bacteria are considered potent producers of bioactive natural compounds, due to their versatile biocatalytic activity. The present study aims to isolate, identify, and analyze four novel bacterial strains that have the potential to produce NPs. The novelty was determined via taxonomical assessment using various biochemical and quantitative antagonistic screening assays. 16S rRNA molecular characterization and bioinformatics analysis identified the isolates as Klebsiella pneumoniae strain ABSKSLAB01, Klebsiella quasipneumonia strain ABSKSLAB02, Streptomyces minutiscleroticus strain ABSKSLAB03, and Streptomyces peucetius strain ABSKSLAB04. Their bacterial sequences were deposited in the GenBank database with accession numbers ‘OP597532’, ‘OP597545’, ‘OQ061473’, and ‘PP086938’, respectively. Among all the bacterial strains, ABSKSLAB04 demonstrated the highest antagonistic activity and the potential to produce NPs. Further optimization studies using the OVAT approach and statistical investigations via Plackett–Burman, RSM–Box–Behnken design, and artificial neural network rendered the optimized culture conditions to produce NPs: pH 7 ± 1.2, temperature 40 ± 5 °C, and inositol concentration of 5.5 ± 1.5, resulting in maximum antagonistic activity of 29.81 mm. The ANN model reflected superior predictive capacity compared to the RSM model with enhanced statistical metrics: R2 (92.23%), MSE (0.0277), and RMSE (0.1477). ANN optimized production yield was measured at 580 mg/L, reflecting a 1.57-fold enhancement over the pre-optimized conditions (370 mg/L), and a 1.22-fold improvement compared to the RSM model (450 mg/L). This highlighted the ANN model’s robustness in modeling complex nonlinear relationships and optimizing the bioprocess parameters with higher fidelity. Therefore, the results from the study conclude the potential of the designated bacterial strain (ABSKSLAB04) to produce NPs with enhanced antimicrobial and antineoplastic characteristics. The strain can further be utilized in biotechnological paradigms by scaling up in the pharmaceutical and industrial sectors for therapeutic applications.
- 3 June 2025
- Published by Bentham Science Publishers Ltd. in Medicinal Chemistry
- Vol. 21, 1-22
Potential Inhibitors of SARS-CoV-2 Developed through Machine Learning, Molecular Docking, and MD Simulation
Background: The advent of Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of the Coronavirus Disease 2019 (COVID-19) pandemic, has impacted physical and mental health worldwide. The lack of effective antiviral drugs necessitates a robust therapeutic approach to develop anti-SARS-CoV-2 drugs. Various investigations have recognized ACE2 as the primary receptor of SARS-CoV-2, and this amalgamation of ACE2 with the spike protein of the coronavirus is paramount for viral entry into the host cells and inducing infection. Consequently, restricting the virus';s accessibility to ACE2 offers an alternative therapeutic approach to averting this illness. Objective: The study aimed to identify potent inhibitors with enhanced affinity for the ACE2 protein and validate their stability and efficacy against established inhibitors via molecular docking, machine learning, and MD simulations. Methodology: 202 ACE2 inhibitors (PDB ID and 6LZG), comprising repurposed antiviral compounds and specific ACE2 inhibitors, were selected for molecular docking. The two most effective compounds obtained from docking were further analyzed using machine learning to identify potential compounds with enhanced ACE2-binding affinity. To refine the dataset, molecular decoys were generated through the Database of Useful Decoys: Enhanced (DUD-E) server, and Singular Value Decomposition (SVD) was applied for data preprocessing. The Tree-based Pipeline Optimization Tool (TPOT) was then utilized to optimize the machine learning pipeline. The most promising ML-predicted compounds were re-evaluated through docking and subjected to Molecular Dynamics (MD) simulations to evaluate their structural stability and interactions with ACE2. Finally, these compounds were evaluated against the top two pre-established inhibitors using various computational tools. Results: The two best pre-established inhibitors were identified as Birinapant and Elbasvir, while the best machine-learning-predicted compounds were PubChem ID: 23658468 and PubChem ID: 117637105. Pharmacophore studies were conducted on the most effective machine-learning-predicted compounds, followed by a comparative ADME/T analysis between the best ML-screened and pre-established inhibitors. The results indicated that the top ML compound (PubChem ID: 23658468) demonstrated favorable BBB permeability and a high HIA index, highlighting its potential for therapeutic applications. The ML-screened ligand demonstrated structural stability with an RMSD (0.24 nm) and greater global stability (Rg: 2.08 nm) than Birinapant. Hydrogen bonding interactions further validated their strong binding affinity. MM/PBSA analysis confirmed the ML-screened compound';s stronger binding affinity, with a binding free energy of - 132.90 kcal/mol, indicating enhanced stability in complex formation. Conclusion: The results emphasize the efficacy of integrating molecular docking, machine learning, and molecular dynamics simulations in facilitating the rapid identification of novel inhibitors. PubChem ID: 23658468 demonstrates robust binding affinity to ACE2 and favorable pharmacokinetic properties, establishing it as a promising candidate for further investigation.
- 3 June 2025
- Published by Bentham Science Publishers Ltd. in Medicinal Chemistry
- Vol. 21, 1-22
Potential Inhibitors of SARS-CoV-2 Developed through Machine Learning, Molecular Docking, and MD Simulation
Background: The advent of Severe Acute Respiratory Syndrome coronavirus 2 (SARS-CoV-2), the etiological agent of the Coronavirus Disease 2019 (COVID-19) pandemic, has impacted physical and mental health worldwide. The lack of effective antiviral drugs necessitates a robust therapeutic approach to develop anti-SARS-CoV-2 drugs. Various investigations have recognized ACE2 as the primary receptor of SARS-CoV-2, and this amalgamation of ACE2 with the spike protein of the coronavirus is paramount for viral entry into the host cells and inducing infection. Consequently, restricting the virus';s accessibility to ACE2 offers an alternative therapeutic approach to averting this illness. Objective: The study aimed to identify potent inhibitors with enhanced affinity for the ACE2 protein and validate their stability and efficacy against established inhibitors via molecular docking, machine learning, and MD simulations. Methodology: 202 ACE2 inhibitors (PDB ID and 6LZG), comprising repurposed antiviral compounds and specific ACE2 inhibitors, were selected for molecular docking. The two most effective compounds obtained from docking were further analyzed using machine learning to identify potential compounds with enhanced ACE2-binding affinity. To refine the dataset, molecular decoys were generated through the Database of Useful Decoys: Enhanced (DUD-E) server, and Singular Value Decomposition (SVD) was applied for data preprocessing. The Tree-based Pipeline Optimization Tool (TPOT) was then utilized to optimize the machine learning pipeline. The most promising ML-predicted compounds were re-evaluated through docking and subjected to Molecular Dynamics (MD) simulations to evaluate their structural stability and interactions with ACE2. Finally, these compounds were evaluated against the top two pre-established inhibitors using various computational tools. Results: The two best pre-established inhibitors were identified as Birinapant and Elbasvir, while the best machine-learning-predicted compounds were PubChem ID: 23658468 and PubChem ID: 117637105. Pharmacophore studies were conducted on the most effective machine-learning-predicted compounds, followed by a comparative ADME/T analysis between the best ML-screened and pre-established inhibitors. The results indicated that the top ML compound (PubChem ID: 23658468) demonstrated favorable BBB permeability and a high HIA index, highlighting its potential for therapeutic applications. The ML-screened ligand demonstrated structural stability with an RMSD (0.24 nm) and greater global stability (Rg: 2.08 nm) than Birinapant. Hydrogen bonding interactions further validated their strong binding affinity. MM/PBSA analysis confirmed the ML-screened compound';s stronger binding affinity, with a binding free energy of - 132.90 kcal/mol, indicating enhanced stability in complex formation. Conclusion: The results emphasize the efficacy of integrating molecular docking, machine learning, and molecular dynamics simulations in facilitating the rapid identification of novel inhibitors. PubChem ID: 23658468 demonstrates robust binding affinity to ACE2 and favorable pharmacokinetic properties, establishing it as a promising candidate for further investigation.
- 1 March 2025
- Published by Bentham Science Publishers Ltd. in Current Biotechnology
- Vol. 14 (1) , 52-76
Identification and Characterization of Biosurfactant-producing Novel Paenibacillus dendritiformis Strain ANSKLAB02 from Brackish River Water
Introduction: Biosurfactants are the surface-active reagents produced by microorgan-isms, which exhibit the non-toxic and augmented bioavailability potential for the decomposition of petro-based pollutants and performing microbial-enhanced oil recovery (MEOR). Methods: Thus, the present study entails the isolation of a novel biosurfactant-producing bacteria in MSM medium containing crude oil as a sole carbon source. Biosurfactant screening, cultural, and statistical optimization; Plackett - Burman Design, and response surface methodology (RSM) in conjunction with the Box-Behnken experimental design was employed for examining the bio-surfactant producing potential, and emulsification activity of the Paenibacillus strain, which ren-dered a maximum E24 index as 70%, with reduced surface tension of 29 mN/m. Result: The novel isolate was identified and named Paenibacillus dendritiformis strain AN-SKSLAB02 and the sequence was deposited in the NCBI-GenBank database with accession num-ber “KU518891”. Conclusion: The results signify that the bacterium holds the potential to burgeon in harsh condi-tions which is an appropriate habitat for application in MEOR, which has great potential to aid in environmental cleanup.
- 1 March 2025
- Published by Bentham Science Publishers Ltd. in Current Biotechnology
- Vol. 14 (1) , 52-76
Identification and Characterization of Biosurfactant-producing Novel Paenibacillus dendritiformis Strain ANSKLAB02 from Brackish River Water
Introduction: Biosurfactants are the surface-active reagents produced by microorgan-isms, which exhibit the non-toxic and augmented bioavailability potential for the decomposition of petro-based pollutants and performing microbial-enhanced oil recovery (MEOR). Methods: Thus, the present study entails the isolation of a novel biosurfactant-producing bacteria in MSM medium containing crude oil as a sole carbon source. Biosurfactant screening, cultural, and statistical optimization; Plackett - Burman Design, and response surface methodology (RSM) in conjunction with the Box-Behnken experimental design was employed for examining the bio-surfactant producing potential, and emulsification activity of the Paenibacillus strain, which ren-dered a maximum E24 index as 70%, with reduced surface tension of 29 mN/m. Result: The novel isolate was identified and named Paenibacillus dendritiformis strain AN-SKSLAB02 and the sequence was deposited in the NCBI-GenBank database with accession num-ber “KU518891”. Conclusion: The results signify that the bacterium holds the potential to burgeon in harsh condi-tions which is an appropriate habitat for application in MEOR, which has great potential to aid in environmental cleanup.
- 12 March 2024
- Published by Bentham Science Publishers Ltd. in Medicinal Chemistry
- Vol. 20 (3) , 352-368
Unveiling the ESR1 Conformational Stability and Screening Potent Inhibitors for Breast Cancer Treatment
Background: The current study recognizes the significance of estrogen receptor alpha (ERα) as a member of the nuclear receptor protein family, which holds a central role in the pathophysiology of breast cancer. ERα serves as a valuable prognostic marker, with its established relevance in predicting disease outcomes and treatment responses. Methods: In this study, computational methods are utilized to search for suitable drug-like compounds that demonstrate analogous ligand binding kinetics to ERα. Results: Docking-based simulation screened out the top 5 compounds - ZINC13377936, NCI35753, ZINC35465238, ZINC14726791, and NCI663569 against the targeted protein. Further, their dynamics studies reveal that the compounds ZINC13377936 and NCI35753 exhibit the highest binding stability and affinity. Conclusion: Anticipating the competitive inhibition of ERα protein expression in breast cancer, we envision that both ZINC13377936 and NCI35753 compounds hold substantial promise as potential therapeutic agents. These candidates warrant thorough consideration for rigorous In vitro and In vivo evaluations within the context of clinical trials. The findings from this current investigation carry significant implications for the advancement of future diagnostic and therapeutic approaches for breast cancer.
- 12 March 2024
- Published by Bentham Science Publishers Ltd. in Medicinal Chemistry
- Vol. 20 (3) , 352-368
Unveiling the ESR1 Conformational Stability and Screening Potent Inhibitors for Breast Cancer Treatment
Background: The current study recognizes the significance of estrogen receptor alpha (ERα) as a member of the nuclear receptor protein family, which holds a central role in the pathophysiology of breast cancer. ERα serves as a valuable prognostic marker, with its established relevance in predicting disease outcomes and treatment responses. Methods: In this study, computational methods are utilized to search for suitable drug-like compounds that demonstrate analogous ligand binding kinetics to ERα. Results: Docking-based simulation screened out the top 5 compounds - ZINC13377936, NCI35753, ZINC35465238, ZINC14726791, and NCI663569 against the targeted protein. Further, their dynamics studies reveal that the compounds ZINC13377936 and NCI35753 exhibit the highest binding stability and affinity. Conclusion: Anticipating the competitive inhibition of ERα protein expression in breast cancer, we envision that both ZINC13377936 and NCI35753 compounds hold substantial promise as potential therapeutic agents. These candidates warrant thorough consideration for rigorous In vitro and In vivo evaluations within the context of clinical trials. The findings from this current investigation carry significant implications for the advancement of future diagnostic and therapeutic approaches for breast cancer.
- 27 April 2022
- Published by Taylor & Francis in Molecular Simulation
- p. 1
Structure-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation and Pharmacokinetic modelling of Cyclooxygenase-2 (COX-2) inhibitor for the clinical treatment of Colorectal Cancer
Colorectal cancer is the third most frequent cause of cancer worldwide and is more prevalent in older individuals of all ages. The recent statistics from World Health Organisation (WHO) on cancer accounted for 1.93 million new cases of colorectal cancer alone, in 2020[1]. The exact cause of this disease is still unknown; however, obesity, sedentary lifestyle, and changed food consumption habit are thought to be driving forces. Earlier clinical studies have found non-steroidal anti-inflammatory drugs (NSAIDs) to be potent in treating colorectal cancer by inhibiting cyclooxygenase enzyme, and further research ascertained cyclooxygenase-2 gene (COX-2) inhibitors to be the most effective chemotherapy treatment. The aim of this study is to find the most effective inhibitor with a superior affinity against COX-2 protein and its pharmacological profile. The pre-established compound, parecoxib (PubChem ID: 119828) was taken up for Structure-based Virtual Screening to identify a novel compound (PubChem ID: 10151468) that has a strong binding affinity than the established compound. Additionally, the comparative studies of both the screened and established compounds were examined using the MD simulation approach to confirm structural stability. Our conclusion suggests that the virtual screened compound (PubChem ID: 10151468) could be a potential therapeutic for the treatment of colorectal cancer.
- 27 April 2022
- Published by Taylor & Francis in Molecular Simulation
- p. 1
Structure-Based Virtual Screening, Molecular Docking, Molecular Dynamics Simulation and Pharmacokinetic modelling of Cyclooxygenase-2 (COX-2) inhibitor for the clinical treatment of Colorectal Cancer
Colorectal cancer is the third most frequent cause of cancer worldwide and is more prevalent in older individuals of all ages. The recent statistics from World Health Organisation (WHO) on cancer accounted for 1.93 million new cases of colorectal cancer alone, in 2020[1]. The exact cause of this disease is still unknown; however, obesity, sedentary lifestyle, and changed food consumption habit are thought to be driving forces. Earlier clinical studies have found non-steroidal anti-inflammatory drugs (NSAIDs) to be potent in treating colorectal cancer by inhibiting cyclooxygenase enzyme, and further research ascertained cyclooxygenase-2 gene (COX-2) inhibitors to be the most effective chemotherapy treatment. The aim of this study is to find the most effective inhibitor with a superior affinity against COX-2 protein and its pharmacological profile. The pre-established compound, parecoxib (PubChem ID: 119828) was taken up for Structure-based Virtual Screening to identify a novel compound (PubChem ID: 10151468) that has a strong binding affinity than the established compound. Additionally, the comparative studies of both the screened and established compounds were examined using the MD simulation approach to confirm structural stability. Our conclusion suggests that the virtual screened compound (PubChem ID: 10151468) could be a potential therapeutic for the treatment of colorectal cancer.
- Open Access
- 15 April 2022
- Published by Taylor & Francis in Journal of Experimental Nanoscience
- Vol. 17 (1) , 247-273
Synthesis, crystal structure, hirshfeld surface analysis, molecular docking and molecular dynamics studies of novel olanzapinium 2,5-dihydroxybenzoate as potential and active antipsychotic compound
The antipsychotic drug Olanzapine was crystallized with aromatic acid, 2,5-dihydroxybenzoic acid in isopropyl alcohol by slow evaporation which led to the formation of olanzapinium 2,5-dihydroxybenzoate crystalline salt. The structure of the compound was characterized by 1H-NMR, 13C-NMR, and single-crystal X-ray diffraction analysis. The Hirshfeld analyses were performed to quantify the order and nature of intermolecular interactions in the crystal network. Employing computational approaches, the compound was tested for its affinity against antipsychotic activity by molecular docking and molecular dynamic simulation to attest the conformational stability over time step of 100 ns. Besides, bioactivity and ADMET properties were also predicted to ratify the result. The compound asserted neither carcinogenic nor mutagenic activity and has high oral bioavailability. Hence, this synthesized novel compound Olanzapinium 2,5-dihydroxybenzoate recognized in the study possesses high potential as an effective antipsychotic compound, and can further be examined for its efficiency by in vivo studies. The synthesized compound was submitted to NCBI PubChem database using accession substance ID: 441329256. The crystal structure was submitted to CCDC (Cambridge Crystallographic Data Centre) with submission ID: 2010899.
- 15 April 2022
- Published by Taylor & Francis in Journal of Experimental Nanoscience
- Vol. 17 (1) , 247-273
Open AccessSynthesis, crystal structure, hirshfeld surface analysis, molecular docking and molecular dynamics studies of novel olanzapinium 2,5-dihydroxybenzoate as potential and active antipsychotic compound
The antipsychotic drug Olanzapine was crystallized with aromatic acid, 2,5-dihydroxybenzoic acid in isopropyl alcohol by slow evaporation which led to the formation of olanzapinium 2,5-dihydroxybenzoate crystalline salt. The structure of the compound was characterized by 1H-NMR, 13C-NMR, and single-crystal X-ray diffraction analysis. The Hirshfeld analyses were performed to quantify the order and nature of intermolecular interactions in the crystal network. Employing computational approaches, the compound was tested for its affinity against antipsychotic activity by molecular docking and molecular dynamic simulation to attest the conformational stability over time step of 100 ns. Besides, bioactivity and ADMET properties were also predicted to ratify the result. The compound asserted neither carcinogenic nor mutagenic activity and has high oral bioavailability. Hence, this synthesized novel compound Olanzapinium 2,5-dihydroxybenzoate recognized in the study possesses high potential as an effective antipsychotic compound, and can further be examined for its efficiency by in vivo studies. The synthesized compound was submitted to NCBI PubChem database using accession substance ID: 441329256. The crystal structure was submitted to CCDC (Cambridge Crystallographic Data Centre) with submission ID: 2010899.